Global Premature Ejaculation Therapeutics Market - Focused Insights
2024-2029
The global premature ejaculation (PE) therapeutics market is experiencing significant growth, valued at $2,456.71 million in 2023 and projected to reach $4,062.34 million by 2029, growing at a CAGR of 8.74%. The market's expansion is primarily driven by the increasing prevalence of PE among men globally
To know more,
https://www.focusreports.store/report/premature-ejaculationtherapeutics-market-focused-insights
Premature ejaculation is a prevalent sexual problem, affecting about 20-30% of men in the sexually active age group. This condition not only causes psychological stress but also impacts self-esteem. The highest incidence is reported among the 18 to 30-year-old age group and, along with erectile dysfunction, in the 45 to 65-year-old age group. PE prevalence varies among different ethnic groups, with higher rates reported among African Americans compared to Hispanics or Whites.
There is a notable demand for disposable syringes in developing economies due to the high cost of sterilization processes for reusable syringes. Safety and prefilled syringes are also increasingly preferred as they reduce risks to medical professionals and ensure accurate drug dosage to patients.
In summary, the global PE therapeutics market is growing and characterized by pharmaceutical companies and generic manufacturers offering off-label branded drugs and generics, with strategic acquisitions and partnerships shaping the competitive landscape.
Highlights
• By drug class, the Selective Serotonin Reuptake Inhibitors (SSRIs) segment was valued at $1,064.41 million in 2023. The increased recommendation of SSRIs by healthcare professionals is one of the key factors for the growth of the segment worldwide. SSRIs are considered effective drugs for the treatment of premature ejaculation therapeutics market.
• The increased recommendation of oral therapeutics by healthcare professionals is one of the key factors for the growth of the oral therapeutics market worldwide. Also, the growing pervasiveness of premature ejaculation and the increasing uptake of generic off-label medications are the key factors enabling the growth of the oral ROA segment.
• The rise in the prevalence of premature ejaculation in the younger population is the major factor contributing to the market growth during the forecast period. The people aged below 45 years segment is going to drive the demand for premature ejaculation therapeutics.
Regional Analysis
In 2023, North America and Europe dominated the market, while the Asia-Pacific region is expected to be the fastest-growing market for PE therapeutics, with a CAGR of 10.56%.
The North American region, particularly the United States, leads in revenue generation, followed by Europe, Asia-Pacific, Latin America, and the Middle East and Africa (MEA). North America also has the highest incremental growth, fueling the global PE therapeutics market.
Vendor Landscape
The global PE therapeutics market is witnessing strategic initiatives by key vendors, leading to intensifying market competitiveness. Major players like Pfizer, Bayer, Eli Lilly and Company, and GlaxoSmithKline offer off-label drugs for PE treatment, with physicians prescribing wellknown brands as off-label medications